Phenylalkylcarboxylic acid delivery agents

1. A composition comprising:

(A) a biologically active agent; and

(B) a delivery agent compound selected from

3-(3-phenoxyphenyl)propanoic acid,

4-(4-ethylphenyl)butanoic acid,

5-(4-ethylphenyl)pentanoic acid,

and pharmaceutically acceptable salts thereof.

2. The composition of claim 1 , wherein the delivery agent compound is 3-(3-phenoxyphenyl)propanoic acid, or a pharmaceutically acceptable salt thereof.

3. The composition of claim 1 , wherein the delivery agent compound is 4-(4-ethylphenyl)butanoic acid, or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1 , wherein the delivery agent compound is 5-(4-ethylphenyl)pentanoic acid, or a pharmaceutically acceptable salt thereof.

5. The composition of claim 1 , wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof.

6. The composition of claim 1 , wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, glucagon, interferons, α-interferon, β-interferon, γ-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; gallium or gallium salts; glucagons; zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, caspofungin acetate, CPHPC, siRNA and any combination thereof.

7. The composition of claim 1 , further comprising at least one enzyme inhibitor.

8. The composition of claim 1 , wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, heparin, recombinant human growth hormone, glucagon, caspofungin acetate, calcitonin, PTH, zanamivir, erythropoietin, analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof.

9. A method of preparing pharmaceutical composition, comprising mixing a delivery agent compound selected from 3-(3-phenoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 5-(4-ethylphenyl)pentanoic acid, and pharmaceutically acceptable salts thereof, and a biologically active agent.

10. The method of claim 9 , wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof.

11. The method of claim 9 , wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, glucagon, interferons, α-interferon, β-interferon, γ-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; gallium or gallium salts; glucagons; zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, caspofungin acetate, CPHPC, siRNA and any combination thereof.

12. A dosage unit form comprising:

(A) a delivery agent compound selected from 3-(3-phenoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 5-(4-ethylphenyl)pentanoic acid, and pharmaceutically acceptable salts thereof;

(B) a biologically active agent; and

(C) (a) an excipient;

(b) a diluent;

(c) a disintegrant;

(d) a lubricant;

(e) a plasticizer;

(f) a colorant;

(g) an enzyme inhibitor;

(h) a dosing vehicle; or

(i) any combination thereof.

13. The dosage unit form of claim 12 , wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof.

14. The dosage unit form of claim 12 , wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, interferons, glucagon, α-interferon, β-interferon, γ-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor, insulin-like growth factor-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine, parathyroid hormone, fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; gallium or gallium salts; glucagons, zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, capsofungin acetate, CPHPC, SiRNA and any combination thereof.

15. The dosage unit form of claim 12 , wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, heparin, recombinant human growth hormone, glucagon, caspofungin acetate, calcitonin, parathyroid hormone, zanamivir, erythropoietin, and any combination thereof.

16. The dosage unit form of claim 12 , wherein the dosage unit form is a tablet, a capsule, a powder, or a liquid.

17. The dosage unit form of claim 12 , wherein the dosing vehicle is a liquid selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

18. A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering to the animal the composition of claim 1 .

19. The method of claim 18 , wherein the composition is administered intranasally, sublingually, intraduodenally, subcutaneously, buccally, intracolonicly, rectally, vaginally, muco sally, pulmonary, transdermally, intradermally, parenterally, intravenously, intramuscularly, via the ocular system, or by traversing the blood-brain barrier.

20. The method of claim 18 , wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof.

21. The method of claim 18 , wherein the composition is administered orally.